Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621517 · ClinicalTrials.gov registry record · Phase 2
Bupropion and Restless Legs Syndrome
A Phase 2 study of Restless Legs Syndrome, sponsored by East Tennessee State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00621517: Completed Phase 2 study of Restless Legs Syndrome, sponsored by East Tennessee State University.
NCT00621517 is a Phase 2 study of Restless Legs Syndrome that has completed, run by East Tennessee State University. The registered enrollment target is 60 participants, below the 92-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00621517, a Phase 2 study of Restless Legs Syndrome, has completed, sponsored by East Tennessee State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if bupropion will improve the symptoms of restless legs syndrome (RLS).
Primary Outcome
Scale ranges from 0 to 40 points with higher scores being associated with more severe symptoms of restless legs syndrome. There are 10 questions, with points of 0 to 4 per question. The change in IRLSSG score from baseline is recorded at three and six weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bupropion
Study Locations (1)
Tennessee
- East Tennessee State University - Johnson City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00621517 record still lists
NCT00621517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 92-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Restless Legs Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00621517 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00621517 about?
NCT00621517 is a clinical study titled "Bupropion and Restless Legs Syndrome". The purpose of this study is to determine if bupropion will improve the symptoms of restless legs syndrome (RLS).
What is the current status of trial NCT00621517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2008-02. Estimated completion is 2009-07.
What conditions does trial NCT00621517 study?
This clinical trial studies the following conditions: Restless Legs Syndrome.
What interventions are being tested in trial NCT00621517?
The interventions under investigation include: Placebo (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT00621517?
This trial is sponsored by East Tennessee State University, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00621517 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00621517's enrollment target sits among peer trials
60 6th of 14 higher than 9 of 14 other Restless Legs Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Restless Legs Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Simulated Driving Study in Restless Legs Syndrome
COMPLETED · Phase 2
-
Blood Changes After Exercise in Restless Legs Syndrome
RECRUITING · NA
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Response to an Investigational Device in Patients With Restless Legs Syndrome
ACTIVE NOT RECRUITING · NA
-
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
ACTIVE NOT RECRUITING
-
Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia